Abstract 3720
Background
Several treatment options are currently available for patients with mCRPC who were treated with a docetaxel-containing regimen. As one therapeutic option, cabazitaxel (CABA) in combination with prednis(ol)one can be administered. SCOPE is the first multinational, non-interventional study to address this question prospectively.
Methods
Within the ongoing SCOPE study, data on medical history, therapeutic management and outcome of mCRPC patients starting treatment with CABA under routine conditions are assessed with a target recruitment of 900 patients. For the current interim analysis (cut-off: MAR 16, 2018) descriptive statistics were used to analyze preliminary data on treatment outcomes.
Results
Of 551 enrolled patients, 137 patients (median age: 73 (47 to 88) years, ECOG of ≤ 1: 81.8%, median duration of CRPC at study inclusion: 20.4 (0.8 to 109.1) months) have completed CABA therapy. For 27 patients, first line therapy with an androgen-receptor targeted agent (ARTA) was documented (ARTA 1st line), of which 10 patients received an ARTA in 2nd line (ARTA post ARTA). None (0.0%) of the 10 ARTA post-ARTA patients had reductions in PSA levels ≥50% (PSA50 response) compared to baseline. Median progression-free survival (PFS) after the start of the respective therapy was longer for 1st line ARTA than for ARTA post-ARTA therapy (10.8 vs. 3.5 months, p = 0.0106). Fifty patients received docetaxel as 1st line therapy directly followed by CABA (CABA 2nd line) and for 24 patients ARTA therapy was documented after docetaxel and prior to CABA (CABA 3rd line). PSA50 response to CABA was 38.0% (CABA 2nd line) and 37.5% (CABA 3rd line), respectively. Median PFS after start of CABA therapy showed no significant differences between the CABA 2nd line and CABA 3rd line group (4.2 vs. 5.1 months, p = 0.5663).
Conclusions
The current results indicate that the outcome of ARTA post-ARTA is unfavourable compared to 1st line ARTA therapy and that CABA is effective in both ARTA and docetaxel refractory patients. However, interpretation of results is challenging due to the highly diverse treatment sequences administered in patients with mCRPC under routine conditions.
Clinical trial identification
BfArM data base No: 6658.
Legal entity responsible for the study
Sanofi Aventis Deutschland GmbH.
Funding
Sanofi Aventis Deutschand GmbH.
Editorial Acknowledgement
Disclosure
J. Gschwend: Lectures: Amgen, Astellas, Bayer, Janssen, MSD, Novartis, Roche, Sanofi; Advisor role: Bayer, BMS, Janssen, MSD, Novartis, Pfizer, Roche. C. Bokemeyer: Honoraria: Merck KGaA, Sanofi, Roche, Bayer, Brystol-Meyer Squibb, Servier/Pfizer, AstraZeneca; Consulting: Lilly/ImClone, Merck Serono, Sanofi, Mundipharma, Bayer Schering Pharma, Hexal. All other authors have declared no conflicts of interest.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract